NRPs (neuropilins) are receptors for class 3 semaphorins, polypeptides essential for axonal guidance, and for members of the VEGF (vascular endothelial growth factor) family of angiogenic cytokines. While mutant mouse studies show that NRP1 is essential for neuronal and cardiovascular development, little is known concerning the molecular mechanisms through which NRPs mediate the functions of their ligands in different cell types. NRP1 forms complexes with its co-receptors and is required for optimal function, but NRPs lack a clearly defined signalling domain and the role of NRP1 in receptor signalling and the function of the NRP1 cytosolic domain are unclear. Growing evidence indicates, however, that NRP1 plays a selective role in signalling at least in part via its C-terminal domain and interaction with intracellular binding partners.
Introduction
NRP1 (neuropilin-1) and the related molecule, NRP2, are receptors both for class 3 semaphorins, a family of secreted polypeptides with key roles in axonal guidance, and for specific members of the VEGF (vascular endothelial growth factor) family of angiogenic cytokines. The embryonic lethality and phenotype of NRP1-deficient mice have confirmed essential functions of NRP1 in neuronal and cardiovascular development, and NRP1 is also implicated in an increasingly diverse range of physiological and disease-related processes, including tumour progression, T-cell activation and viral infection [1, 2] . However, despite the flow of information about biological roles of NRPs, much about the molecular mechanisms through which NRPs mediate the functions of their ligands in different cell types remains enigmatic.
Structure and biological function
NRP1 and NRP2 are transmembrane glycoproteins of up to 923 and 926 amino acids, respectively, with an overall amino acid homology of 44%. The large NRP extracellular region contains two CUB (complement protein subcomponents C1r/C1s, urchin embryonic growth factor and bone morphogenetic protein 1) (a1/a2) domains essential for semaphorin binding, two factor V/VIII homology (b1/b2) domains, required for VEGF and semaphorin binding, and a MAM (meprin/A-5 protein/receptor protein-tyrosine phosphatase μ) (c) domain, which may be involved in NRP1 homodimerization or oligomerization [1] (see Figure 1 ). NRPs also possess small cytoplasmic domains (44 and 43 amino acids for NRP1 and NRP2, respectively) ( NRP1 is modified by O-linked glycosylation at Ser 612 to form a high-molecular mass species (>250 kDa) by addition of CS-GAG (chondroitin sulfate glycosaminoglycan) in some tumour cells [3] , or both heparin sulfate and CS-GAGs in VSMCs (vascular smooth-muscle cells) [4] . Interestingly, GAG-modified NRP1 is not expressed or is expressed at a very low level in cultured human endothelial cells and NRP2 also does not appear to undergo GAG modification in any cell type examined so far ( [3, 4] ; and C. Pellet-Many, P. Frankel, I.M. Evans, B. Herzog, M. Jünemann-Ramírez and I.C. Zachary, unpublished work). Overexpression of a nonmodifiable S612A NRP1 mutant in human malignant glioma U87MG cells enhanced cell invasion in a three-dimensional collagen matrix, and GAG-modified NRP1 was weakly expressed in biopsies of late stage human malignant gliomas, suggesting that O-linked glycosylation is a potentially important point of regulation in cell functions mediated by NRP1 [3] .
NRPs are unusual in their ability to bind with high affinity two structurally unrelated classes of ligands with distinct biological functions, the class 3 semaphorins and members of the VEGF family. Specific ligand interactions are summarized in Figure 1 . The major semaphorin ligand for NRP1 is Sema3A (also named collapsin-1), which induces collapse of the growth cone in selected sensory and sympathetic neurons, such as the DRG (dorsal root ganglion), and is essential for neurogenesis in development [5] .
Figure 1 NRP cytosolic domains
Class 3 semaphorins bind NRP1 and NRP2 with differing, and partially overlapping, specificities and affinities. Plexins A1 and A2 are the major signalling receptors for class 3 semaphorins, and complex with NRPs and semaphorins to mediate effects of semaphorins on growth cone collapse and axonal guidance in neurogenesis. The plexin cytoplasmic domain contains two blocks of homology shared with GAPs. Specific isoforms of several members of the VEGF family bind with high affinity to NRP1 and NRP2, with distinct specificities. VEGF specificities for their receptor tyrosine kinases are also shown. The major VEGF-A signalling receptor, VEGFR2 complexes with NRP1 and is important for optimal VEGFR2 signalling and function in endothelial cells. NRP functions are inferred from the phenotypes of NRP mutant mice. NRP1 has also been reported to associate with VEGFR1/Flt-1 (Fms-like tyrosine kinase-1), and NRP2 can complex with the receptor for VEGF-C and VEGF-D, VEGFR3, also called Fms-related tyrosine kinase receptor 4 (VEGFR3/Flt-4). See text and [1] for further details. Key: Ig-like, immunoglobulin-like; IPT, immunoglobulin-like domains shared by plexins and transcription factors; MRS, Met-related sequences. Modified with permission, from [1] . c Biochemical Society.
Figure 2 Mechanisms of NRP action
Sequences of NRP cytosolic domains with the PDZ domain-binding motif underlined, and a putative consensus ITAM domain in NRP2a boxed with key residues underlined.
Whereas the most active and abundant VEGF-A isoform, VEGF-A 165 , contains exons 7 and 8 but lacks exon 6, and is able to bind to both NRP 1 and 2 [6] , the reduced biological activity of VEGF-A 121 has been attributed to its inability to bind NRP1. However, VEGF-A 121 has recently been found to bind NRP1 in vitro probably through its exon 8-encoded domain, though it appears unable to promote NRP1-VEGFR2 (VEGF receptor 2) heterocomplex formation [7] . The less biologically active VEGF-A 165 b isoform has a distinct C-terminus encoded by an alternative exon 8 and is unable to stimulate endothelial cell proliferation or angiogenesis, probably due to its inability to bind NRP1 [8, 9] . Other factors may also influence VEGF binding to NRP1, including heparin, the density of NRP1 [10] and CS-GAG modification [4] .
Targeted disruption of NRP1 demonstrates an essential role for this molecule in neurogenesis and cardiovascular development (reviewed in [1] ). NRP1-null mice die between E12 and E13.5 (embryonic days 12 and 13.5) with a spectrum of cardiovascular and neuronal defects [5] . Some degree of separation of neuronal and endothelial roles of NRP1 is indicated by the finding that, whereas the embryonic lethality of endothelial-specific NRP1 knockout mice is largely attributable to major cardiovascular defects, knockin mice unable to bind Sema3A but retaining the ability to bind VEGF-A, survive through embryogenesis, possess no obvious cardiovascular defects, but exhibit defasciculation and aberrant pathfinding of sensory nerves, dying shortly after birth [11] . NRP2-null mice survive to adulthood with no obvious cardiovascular abnormalities, but exhibit a severe reduction of small lymphatic vessels and capillaries, as well as abnormal guidance and fasciculation of nerves [12] . Doubly deficient NRP1
−/− /NRP2 −/− mice exhibit earlier embryonic mortality than the NRP1 knockout and have a more severe vascular phenotype resembling the VEGF-A 165 and VEGFR2 [Flk-1 (fetal liver kinase-1), equivalent to human KDR (kinase insert domain-containing receptor)] knockouts [13] . Broadly consistent with findings in NRP1 mice, studies in cell cultures are most strongly indicative of a role of NRP1 in cell migration and adhesion [1] , though the biological response is determined by the ligand and cell type: mainly chemorepulsion in neurons stimulated by Sema3A [14] and chemoattraction in VEGF-responsive endothelial cells [15, 16] .
Receptors and signalling mechanisms
Neuronal cells NRP1 mediates the chemorepulsive effects of Sema3A by acting as the ligand-binding component of a complex or holoreceptor between NRP1 and specific members of a family of transmembrane receptors called plexins [17, 18] . NRP1 and NRP2 form complexes with several plexins independently of the presence of semaphorins, including plexins A1, A2, A3 and B1 [1] . Plexins are large transmembrane receptors with an intracellular domain containing two conserved regions, the functions of which are not yet clearly defined, but show some homology to Ras-GAP (GTPase-activating protein) domains, and which, in the case of plexin B1, has been shown to act as a GAP for R-Ras [19] . Sema3A contains both an NRP-binding site and potential sites of interaction with Plexins. It has been proposed that Sema3A binding results in a 2:2:2 complex between Sema3A, plexin A1 and NRP1, and involves relief of autoinhibition of plexin A1 [20] , leading to activation of the plexin intracellular domain and the transduction of chemorepulsive signals. Class 3 semaphorins have different affinities for NRP1 and NRP2 and require distinct plexins to transduce their signal. Thus, in sensory neurons NRP1 acts mainly through plexin A4, whereas signalling via NRP2 is mediated largely by plexin A3 [21] .
The plexin cytoplasmic domain is responsible for chemorepellent signalling induced by semaphorins and resulting in the collapse of neurons [17, 18] , in part via small GTPases [22] [23] [24] [25] . Cytoskeletal collapse induced by recruitment of Rnd to the plexin A1 cytoplasmic domain is antagonized by RhoD, which is also able to bind to plexin A1 [23] . Sema3A-induced cytoskeletal collapse in Cos-7 cells was dependent on co-transfection of plexin A1 and NRP1, and involved a direct interaction between Rac and plexin A1 [24, 25] . However, since deletion of the cytoplasmic domain of NRP1 did not impair sema3A signalling [26] , NRP1 appears to function in Sema3A-induced chemorepulsion primarily as a binding module.
The immunoglobulin superfamily cell adhesion molecule, L1, may also complex with NRP1 in mediating chemorepulsive Sema3A signals. L1 and NRP1 form stable complexes mediated by interactions between their extracellular domains [27] , and L1-deficient cortical axons are unable to respond to Sema3A repulsive cues [28] , findings which may explain some of the phenotypic characteristics of L1-deficient mice, such as reduced sensitivity to touch and pain, lack of hind limb co-ordination, a smaller corticospinal tract and reduced association of Schwann cells with axons [29] . Moreover, L1 mutations located in the NRP1-binding region are associated with the neurological disorders, X-linked hydrocephalus and MASA (Mental retardation, Aphasia, Shuffling gait, Adduced thumbs) syndrome. The L120V mutation disrupts L1 association with NRP1, implicating defective L1/NRP1 signalling in the pathogenesis of the disease [27] . Soluble L1 extracellular domain is able to convert repulsive Sema3A signals into chemoattraction by binding in trans to NRP1 and this conversion is mediated by nitric oxide-dependent activation of guanylate cyclase and consequent cGMP synthesis [27] . The effects of L1 deficiency do not phenocopy the neural defects of Sema3A-deficient mice or NRP1 sema3A−/− mice expressing mutant NRP1 unable to bind Sema3A, indicating that L1 regulates Sema3A signalling via NRP1 in a more restricted set of neurons. It is also unclear whether the L1/NRP1 complex interacts with plexin/NRP1 holoreceptors.
Endothelial cells
In endothelial cells, NRP1 is thought to act primarily as a co-receptor for VEGF-A 165 by forming complexes with the VEGF protein tyrosine kinase receptor, VEGFR2/KDR. Co-expression of NRP1 with VEGFR2 enhances VEGF binding to VEGFR2, VEGFR2 phosphorylation and VEGFinduced signalling and migration [16, [30] [31] [32] , and association between NRP1 and VEGFR2 has been demonstrated by co-immunoprecipitation [9, 15, [30] [31] [32] [33] [34] . Whether or not NRP1 increases the affinity of VEGFR2/KDR for VEGF-A remains uncertain, some studies suggesting that NRP1 has little effect on VEGF affinity for its receptors [30] , others indicating that NRP1 enhances VEGFR2 affinity for VEGF [35] . There is also controversy as to whether NRP1/VEGFR2 complexation is ligand-dependent, some groups reporting VEGF-induced NRP1 association with VEGFR2 [15, 31] , others observing VEGF-A-independent or constitutive complex formation [30, 35] . Deletion of the PDZ domain-binding motif in the NRP1 cytosolic domain reduced co-immunoprecipitation of NRP1 with VEGFR2 [36] , suggesting that intracellular interactions may play as important a role in heterocomplex formation as ligand binding.
Signalling via VEGFR2 can be triggered by VEGF-A independently of NRP1 [37] , and selective inhibition of VEGF-A binding to NRP1 using a specific peptide antagonist attenuated rather than blocked VEGF-induced VEGFR2 tyrosine phosphorylation, and activation of ERK (extracellular-signal-regulated kinase) and phospholipase Cγ , and prostacyclin production, but had less effect on Akt (protein kinase B) activation and did not reduce the cell survival or proliferative responses to VEGF [9] . Similarly, antibodies that specifically block VEGF binding to NRP1 prevented NRP1 complexation with VEGFR2, and reduced VEGF-stimulated migration to approx. 50% of control responses, but had little effect on VEGFR2 phosphorylation, p38 kinase activation, and permeability [15] . Another study shows that VEGFs that bind both VEGFR2 and NRP1, such as VEGF-A 165 and the VEGF-E-NZ2 subtype, are more angiogenic and induce more p38 kinase activity than VEGF-A 121 [38] . These findings indicate that NRP1 is not necessary for VEGFR2 activation, or for the full palette of signalling pathways and biological responses stimulated by VEGF, but may be required for some biological functions, particularly migration, and for optimal VEGF-induced VEGFR2 signalling, though the pathways in question remain poorly defined. Key questions emerging out of these studies are whether NRP1 and/or VEGFR2/NRP1 complexes are required for optimal signalling through VEGR2 across the full spectrum of signalling events, or whether NRP1 recruits or links specific signalling networks to the VEGF/VEGFR2 axis. While much of the evidence for a role of NRP1 in VEGF signalling is based on the differential biological activities of NRP1-binding and non-binding isoforms, it is also unclear whether VEGF binding to NRP1 is actually necessary for all NRP1 activities in VEGF function. Other important aspects of NRP1/VEGFR2 complexation that remain illdefined include the relationship between VEGFR2 and NRP1 homodimerization and heterocomplexation, the kinetics of VEGFR2/NRP1 associations and how these correlate with key downstream signalling events, and the role of heterocomplexes in endocytosis and trafficking of VEGFR2.
NRP1-dependent signalling via VEGFR2 could occur through a number of mechanisms. Some studies suggest that NRP1/VEGFR2 complex formation, either spontaneous or ligand-dependent, stabilizes or enhances binding of VEGF-A to VEGFR2 [9, 35] . Alternatively, NRP1/VEGFR2 complex formation may stabilize VEGFR2 at the cell surface, rendering it less labile, and/or by retarding receptormediated endocytosis. Either mechanism might be predicted to generally increase the duration and amplitude of receptor activation and downstream signalling ( Figure 3A) . In support of this possibility, siRNA (small interfering RNA)-mediated NRP1 knockdown was recently reported to both reduce KDR expression and attenuate VEGF-induced gene expression in human endothelial cells [39] . A second model is that NRP1/VEGFR2 ligand complexes transduce intracellular signals, perhaps via protein-protein interactions, which serve to co-opt signalling components to NRP1 ( Figure 3B ). Lastly, NRP1 alone might transduce functional signalling as a result of VEGF binding but independent of VEGFR2 ( Figure 3C ). In the last two mechanistic scenarios, the NRP1 cytosolic domain might function as part of a scaffold linking VEGF/VEGFR2 to multimolecular signalling complexes probably close to the plasma membrane, and, we would predict, with important roles in regulation of actin Recent findings indicate that NRP1 is potentially an important point of regulation of signalling pathways converging on phosphorylation of p130Cas in endothelial, tumour and VSMCs, an adaptor protein implicated in cell migration and tumour invasion, which is also a substrate for FAK. See [3] and the text for details.
cytoskeletal dynamics, cell migration, invasion and adhesion. The contribution of NRP1 to VEGF signalling and function may well reflect some combination of all these mechanisms.
We recently identified a potentially important role for NRP1 in regulation of the adapter and actin cytoskeletonassociated protein, p130Cas. Enhanced cell invasion of U87 MG glioma cells overexpressing an NRP1 S612A mutant deficient in O-linked glycosylation, was associated with a striking increase in p130Cas phosphorylation at Tyr 249 compared with control and wild-type NRP1-expressing cells [3] . The S612A NRP1-mediated gain of invasive phenotype was blocked by p130Cas knockdown using siRNA, implicating enhanced p130Cas in NRP1-dependent invasion. The effects of S612A NRP1 expression on p130Cas appeared selective, since levels of activated ERK1/2 or Akt, and Src phosphorylation at Tyr 416 or FAK (focal adhesion kinase) phosphorylation at Tyr 397 were unaltered [3] . Endogenous NRP1 also mediates p130Cas phosphorylation, induced by PDGF (platelet-derived growth factor) and HGF (hepatocyte growth factor) in U87 cells, by VEGF in endothelial cells, and by PDGF in VSMC, and in these disparate cell types, p130Cas phosphorylation also requires the NRP1 cytosolic domain (I.M. Evans, C. Pellet-Many, M. Yamaji, C. Lockie, I.C. Zachary and P. Frankel, unpublished work; and C. Pellet-Many, P. Frankel, I.M. Evans, B. Herzog, M. Jünemann-Ramírez and I.C. Zachary, unpublished work). These findings suggest that NRP1 plays a central role in regulation of the p130Cas pathway, and does so via a signalling or protein-associating function of its intracellular region (Figure 4) . The adaptor protein p130Cas is involved in cytoskeleton reorganization and is a known FAK substrate and FAK-interacting protein. Increased p130Cas tyrosine phosphorylation is associated with increased cell invasion [40] and recruits effector proteins into multimolecular complexes necessary for intracellular signalling. Thus, p130Cas and associated signalling networks involving FAK and other components of focal adhesions or the actin cytoskeleton are prime candidates for specific mediators of NRP1 functions in cell motility mediated by VEGF, or other extracellular cues.
Other cell types and receptors
Recent evidence indicates that NRP1 may be a receptor for other growth factors in the regulation of non-neuronal and non-endothelial cells [41, 42] . Overexpression of NRP1 in pancreatic cancer cells promotes tumour cell invasion and HGF-induced c-Met signalling [43, 44] . NRP1 can associate with c-Met [44] , and NRP1 and NRP2 bind HGF, and mediate HGF stimulation of endothelial cell migration and proliferation [45] . NRP1 also mediates VSMC motility induced by PDGF secreted by breast cancer cells [46] . The role of NRP1 in HGF or PDGF signalling is presently unclear, though, as discussed above, our recent findings indicate a role for NRP1 in signalling pathways converging on p130Cas phosphorylation.
NRP1 has been implicated in T-cell activation and regulation [47] . In the human thymus, NRP1 is expressed at low percentages on all CD4/CD8-defined thymocyte subsets and at high levels on micro-environmental cells, including thymic epithelial and DCs (dendritic cells) [48] . Initial contacts between DCs and resting T-cells causes NRP1 polarization in T-cells and blocking NRP1 antibodies inhibited DC-induced proliferation of resting T-cells, implicating NRP1-mediated interactions between DCs and T-cells in initiation of the primary immune response [47, 49] . NRP1 also regulates Sema3A-mediated thymocyte migration [48] , and is a receptor for TGFβ1 (transforming growth factor β1) and activates the latent form of TGFβ1 in T-cells [42] . Taken together these data demonstrate an emerging role for NRP1 in T-cell function.
NRP1-interacting proteins
The PDZ domain protein, synectin or GIPC1, was identified as an NRP1-interacting protein via an NRP1 consensus PDZ-binding motif (Figure 2) , in a yeast two-hybrid screen [50] . A role for this association in angiogenesis is supported by the finding that expression of NRP1 lacking the C-terminal SEA motif disrupted vessel formation in zebrafish, and that knockdown of either synectin or NRP1 in zebrafish produced similar vascular phenotypes [51] . Furthermore, synectin was found to associate with NRP1 in human endothelial cells, and synectin knockdown inhibited NRP1-mediated endothelial migration [51] .
Synectin binds to G-protein-coupled receptors and modulates their signalling, and interacts with up to 20 other proteins [52] , including integrin α5 and α6 subunits, RGS19 or GAIP, and Rho-GEF (guanine-nucleotide-exchange factor) or syx1 [53] . These findings suggest that synectin may participate in protein scaffolds able to link surface receptors and integrins with intracellular signalling networks. Synectindeficient mice are viable, but the mice are smaller (30% less than littermate controls), and the number of small arteries were significantly reduced, resulting in impaired vascular functions. Arterial (but not venous) endothelial cells from synectin −/− mice exhibited reduced angiogenic responses and aberrant cellular distribution of rac1 in cell culture [54] . As the predominantly microvascular arterial defects in synectin knockout mice do not phenocopy the embryonic lethality or aberrant macrovascular development associated with NRP1 deficiency, not all developmental functions of NRP1 appear to be dependent on synectin association. However, it is possible that other related molecules, such as GIPC2 or GIPC3, may compensate for loss of synectin. Analysis of mutant mice expressing a knock-in mutant lacking the cytosolic NRP1 domain will be useful for probing the role of NRP1 associations with synectin further.
NRP1 may interact with other cellular components. A recent report describes NRP1 association with β1 integrin in modulating pancreatic cancer cell growth, survival and invasion [55] . Epitope-tagged NRP1 immunoprecipitation followed by reverse-phase column chromatography led to the identification of the ectoprotein kinase, CK2 (protein kinase CK2), as a novel associating protein of NRP1, which appears to interact with and phosphorylate the NRP1 extracellular domain [56] . Intriguingly, CK2 phosphorylation of vitronectin is implicated in urokinase-induced adhesion of VSMC [57] . Given that NRP1 plays a role in endothelial cell adhesion and adhesive interactions involving cell-to-cell interactions between T-cells and DCs [1, 47, 49] , it can be speculated that CK2 or other ectoprotein kinases might regulate adhesive functions of the NRP1 extracellular region.
Recent findings suggest that NRP1 has functions independent of its conventional ligands, such as cell adhesion to extracellular matrix. Thus, adhesion of a variety of cell lines is supported by recombinant NRP1 protein via specific regions in the b1 and b2 domains, but was not blocked by Sema3A or VEGF-A 165 [58] . Moreover, siRNA-mediated NRP1 knockdown disrupted endothelial cell adhesion to fibronectin, laminin or gelatin, while VEGFR2 silencing was ineffective [59] . Blocking NRP1 antibodies also have no effect on endothelial cell adhesion to fibronectin [15] , consistent with the independence of an adhesive function from ligand binding. A recent insight into how NRP1 mediates adhesion to matrix comes from a study showing that NRP1-dependent cell adhesion to fibronectin is abrogated in CHO (Chinesehamster ovary) cells lacking α5β1 integrin, and is impaired by deletion of the NRP1 cytosolic domain or SEA motif [60] . Furthermore, synectin association with the NRP1 SEA motif stimulated internalization of α5β1. The likely importance of NRP1 signalling independent of its canonical ligands is underscored further by the disparities between the neurovascular phenotypes of NRP1-null mice and those of mice lacking the major NRP1-binding VEGF isoform, VEGF-A 164 , or both VEGF-A 164 and Sema3A [61, 62] .
NRP1 trafficking
VEGF-A 165 , but not VEGF-A 121 , and Sema3A, reduce cellsurface expression of NRP1 in endothelial and neuronal cells, consistent with receptor-mediated endocytosis and subsequent proteolytic degradation of NRP1 [63] [64] [65] [66] [67] , similar to VEGFR2 (see Bruns et al. [68] , on pp. 1193-1197 of this issue). Studies have reached different conclusions regarding the endocytic pathway followed by NRP1, however, with some suggesting that NRP1 undergoes clathrin-dependent internalization [63] , and others suggesting that NRP1 becomes incorporated into lipid rafts [64, 66] . A recent study shows that NRP1 trafficking is ligand-dependent. Whereas VEGF-A 165 induced clathrin-mediated endocytosis of both NRP1 and VEGFR2 in endothelial cells, Sema3C increased NRP1 internalization and, unlike VEGF-A 165 , also enhanced incorporation of NRP1 in lipid rafts [67] . NRP1 trafficking was reported to be slower in synectin-deficient endothelial cells, indicating a role for NRP1 association with synectin in one or more steps of the NRP1 endocytic pathway [67] . However, many details of the intracellular trafficking of NRP1 and its relevance for function remain to be worked out.
Conclusions
NRP1 forms heterocomplexes with its known co-receptors, VEGFR2 and plexins, and is also known to associate with the PDZ domain protein, synectin, via its cytosolic domain, but the precise role of these complexes in NRP1 function remains to be fully defined. Evidence is emerging which suggests that NRP1 may be important for recruiting or mobilizing specific pathways, such as p130
Cas phosphorylation, to the major receptor signalling axes with which it interacts. Furthermore, the NRP1 cytosolic domain appears to be important for some cellular functions, such as NRP1/VEGFR2 complexation. A selective role for NRP1 in signalling might be consistent with the phenotype of NRP1-deficient mice and the more restricted role of NRP1 in cell migration. However, recent findings are adding to the complexities of NRP1 function. In particular, there is growing evidence for a role of NRP1 both in signalling via the receptors for other growth factors (HGF and PDGF), and in cell types, such as immature T-cells, VSMC and tumour cells, which are not classical targets for either semaphorins or VEGFs. Other lines of evidence indicate that NRP1 can act in through non-canonical modes of action, such as homophilic cell-cell interactions and cell-matrix contacts.
Further work in specific cell types (VSMC, tumour and Tcells) and manipulation of receptor-specific pathways (e.g. HGF, PDGF and TGFβ1) will improve understanding of the signalling mechanisms. Analysis of mutant mice with other tissue-specific knockouts of NRP1 or harbouring domainor function-specific knock-in mutants will also be important for generating further insights into how NRP1 contributes to function and signalling in different organismal systems.
